Schoenherr Thomas Edward sold $874K of TEM

Schoenherr Thomas Edward (CEO, Diagnostics) sold 10,281 shares of Tempus AI, Inc. (TEM) at $85.00 ($0.87M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schoenherr Thomas Edward
Published Sep 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

Provides fresh data on insider holdings and recent disposal.

02

Market read

Insider sales are monitored by traders for potential signals; this modest sale may prompt short‑term caution.

03

What to watch

Potential tax planning or portfolio rebalancing could be driving the transaction.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Thomas Edward Schoenherr sold 10,281 shares for $873,885 via a 10b5‑1 plan.

Expected impact

likely pressure as the market prices in the CEO's share disposal

Evidence & confidence

A $874K sale by the CEO, even under a pre‑arranged plan, can prompt traders to anticipate modest downside.

Market effects

Minimal impact on the broader diagnostics/AI sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale may be routine under a 10b5‑1 plan and not indicate any negative outlook.

Key entities

  • Tempus AI, Inc.

    AI‑driven diagnostics firm.

  • Thomas Edward Schoenherr

    CEO of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.